Literature DB >> 1530532

Complications and failure of anticoagulation therapy in the treatment of venous thromboembolism in patients with disseminated malignancy.

A Chan1, R K Woodruff.   

Abstract

Thirty-one patients with malignancy, anticoagulated for the treatment of venous thromboembolism (VTE) are reported. Complications of treatment included major bleeding (35%), redevelopment of VTE whilst on therapeutic levels of anticoagulants (13%) and recurrent VTE following cessation of anticoagulant (42%). Forty-two per cent of patients died within three months of initiating anticoagulant therapy. The cause of death was progressive malignancy, except in one patient who died of anticoagulant-related bleeding. The high incidence of bleeding is frequently associated with over-anticoagulation and indicates the need for improved monitoring. The frequent recurrence of VTE is associated with chronic disseminated intravascular coagulation, for which warfarin is ineffective and heparin is indicated.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1530532     DOI: 10.1111/j.1445-5994.1992.tb02789.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  4 in total

1.  Oral anticoagulation and risk of death: a medical record linkage study.

Authors:  Anders Odén; Martin Fahlén
Journal:  BMJ       Date:  2002-11-09

Review 2.  Coagulation and cancer: implications for diagnosis and management.

Authors:  M F Loreto ; M De Martinis ; M P Corsi ; M Modesti ; L Ginaldi
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

Review 3.  Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: why hesitate any longer?

Authors:  Philippe Debourdeau; Ismail Elalamy; Axelle de Raignac; Paul Meria; Jean Marc Gornet; Yahovi Amah; Wolfang Korte; Michel Marty; Dominique Farge
Journal:  Support Care Cancer       Date:  2008-08-15       Impact factor: 3.603

Review 4.  Cancer and thrombosis: mechanisms and treatment.

Authors:  Steven R Deitcher
Journal:  J Thromb Thrombolysis       Date:  2003 Aug-Oct       Impact factor: 2.300

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.